Extrastriatal mean regional uptake of fluorine-18-FDOPA in the normal aged brain - An approach using MRI-aided spatial normalization

NeuroImage

Volumn 11, Issue 6 I, 2000, Pages 760-766

  Nagano, Atsuko S ^a,c   Ito, Kengo ^a   Kato, Takashi ^a   Arahata, Yutaka ^a,b   Kachi, Teruhiko ^b   Hatano, Kentaro ^a   Kawasumi, Yasuhiro ^a   Nakamura, Akinori ^a   Yamada, Takako ^b   Abe, Yuji ^b   Ishigaki, Takeo ^c  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b CHUBU NATIONAL HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; FLUORINE 18; LEVODOPA; TRACER;

AGED; AMYGDALOID NUCLEUS; ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; CAUDATE NUCLEUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; MESENCEPHALON; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; STRIATE CORTEX;

EID: 0033946903     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1006/nimg.2000.0584     Document Type: Article

References (38)

1. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:415-455.
2. 2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br. J. Psychiatry 171:444-448.
3. Brooks, D. J., Ibanez, V., Sawle, G. V., et al. 1990. Differing patterns of striatal 18F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 28:547-555.
4. Ernst, M., Zametkin, J., Matochik, J. A., Jons, P. H., and Cohen, R. M. 1998. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [Fluorine-18] fluorodopa positron emission tomographic study. J. Neurol. Sci. 18(15):5901-5907.
5. Fearnley, J. M., and Lees, A. J. 1991. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114:2283-2301.
6. Frackowiak, R. S. J., Friston, K. J., Frith, C. D., Dolan, R. J., and Mazziotta, J. C. (Eds.) 1997. Human Brain Function. Academic Press, San Diego.
7. Garnett, E. S., Firnau, G., and Nahmias, C. 1983. Dopamine visualized in the basal ganglia of living man. Nature 305:137-138.
8. Hoffman, J. M., Melega, W. P., Hawk, T. C., et al. 1992. The effect of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography. J. Neul. Med. 33:1472-1477.
9. Holthoff-Detto, V. A., Kessler, J., Herholz, K., et al. 1997. Functional effects of striatal dysfunction in Parkinson disease. Arch. Neurol. 54:145-150.
10. Ishikawa, T., Dhawan, V., Kazumata, K., et al. 1996. Comparative nigrostriatal dopaminergic imaging with Iodine-123-β CIT-FP/ SPECT and fluorine-18-FDOPA/PET. J. Nucl. Med. 37:1760-1765.
11. Ishiwata, K., Ishii, S., Senda, M., Tsuchiya, Y., and Tomimoto, K. 1993. Electrophilic synthesis of 6-[18F]fluoro-L-DOPA: Use of 4-O-pivaloyl-L-DOPA as a suitable precursor for routine production. Appl. Radiat. Isot. 44:755-759.
12. 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 66:754-758.
13. Jellinger, K. A. 1991. Pathology of Parkinson's disease changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14:153-197.
14. Kish, S. J., Shannak, K., and Hornykiewicz, O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318:876-880.
15. Knable, M. B., and Weinberger, D. R. 1997. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11:123-131.
16. Kretshmann, H. J., and Weinirich, W. 1992. Neurotransmitters and neuromodulators. In Cranial Neuroimaging and Clinical Neuroanatomy, pp. 343-349. Thieme, New York.
17. Kuwabara, H., Cumming, P., Yasuhara, Y., et al. 1995. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J. Nucl. Med. 36:1226-1231.
18. Leenders, K. L., Salmon, E. P., Tyrrell, P., et al. 1990. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol. 47:1290-1298.
19. Maquet, P., Degueldre, C., Delfiore, G., et al. 1997. Functional neuroanatomy of human slow wave sleep. J. Neurol. Sci. 17:2807-2812.
20. Marsden, C. D. 1990. Parkinson's disease. Lancet 335:948-952.
21. Martin, W. R., Palmer, M. R., Patlak, C. S., and Calne, D. B. 1989. Nigrostriatal function in human studied with positron emission tomography. Ann. Neurol. 26:535-542.
22. Martinez Martinez, P. F. A. 1982. Neuroanatomy, pp. 304-307. Nankodo, Tokyo.
23. Ogawa, N. 1995. Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta. Med. Okayama 49(1):1-11.
24. Patlak, C. S., and Blaberg, R. G. 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5:584-590.
25. Patlak, C. S., Blaberg, R. G., and Fenstermacher, J. D. 1983. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1-7.
26. Richardson, M. P., Friston, K. J., Sisodiya, S. M., et al. 1997. Cortical grey matter and benzodiazepine receptors in malformations of cortical development. A voxel-based comparison of structural and functional imaging data. Brain 120:1961-1973.
27. Robb, R. A., and Hanson, D. P. 1991. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys. Eng. Sci. Med. 14:9-30.
28. Roelcke, U., Kappos, L., Lechner-Scott, J., et al. 1997. Reduced glucose metabolism in the frontal cortex and basaal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48:1566-1571.
29. Scatton, B., Rouquier, L., Javoy-Agid, F., and Agid, Y. 1982. Dopamine deficiency in the cerebral cortex in Parkinson disease. Neurology 32:1039-1040.
30. 18F]Fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34(3):324-330.
31. Spence, S. A., Brooks, D. J., Hirsch, S. R., Liddle, P. F., Meehan, J., and Grasby, P. M. 1997. A PET study of voluntary movement in schizophrenic patients experiencing passivity phenomena (delusion of alien control). Brain 120:1997-2011.
32. Takikawa, S., Dhawan, V., Chaly, T., et al. 1995. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: Comparative studies and clinical correlations. J. Nucl. Med. 35:955-963.
33. Talairach, J., and Tournoux, P. 1988. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme, New York.
34. Tison, F., Normand, E., Jaber, M., Aubert, I., Bloch, B. 1991. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninerginc cells of the rat brainstem. Neurosci. Lett. 127:203-206.
35. Wahl, L., Chirakal, R., Firnau, G., Garnett, E. S., and Nahmias, C. 1994. The distribution and kinetics of [18F]6-fluoro-3-O-methyl-L-dopa in the human brain. J. Cereb. Blood Flow Metab. 14:664-670.
36. Weeks, R. A., Cunningham, V. J., Piccomo, P., Waters, S., Harding, A. E., and Brooks, D. J. 1997. 11C-diprenorphine binding in Huntington's disease: A comparison of region of interest analysis with statistical parametric mapping. J. Cereb. Blood Flow Metab. 17: 943-949.
37. Woods, R. P., Cherry, S. R., and Mazziotta, J. C. 1992. Rapid automated algorithm for aligning and reslicing PET images. J. Comput. Assist. Tomogr. 16:620-633.
38. Woods, R. P., Mazziotta, J. C., and Cherry, S. R. 1993. MRI-PET registration with automated algorithm. J. Comput. Assist. Tomogr. 17:536-546.